Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07564674

Investigating the Bioavailability of Broccoli Extract Supplements

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.

Participants will:

* consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) * complete 3 separate 24 hour study cycles * submit blood and urine samples for 24 hours * follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. The amount of glucoraphanin that subjects will take will range from 35-70 mg. Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults, 18-60 years of age
  • Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
  • Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
  • Must be able to give written informed consent

Exclusion criteria

  • Body Mass Index (BMI) <18.5 or >30.0 kg/m2
  • Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
  • Pregnancy, breastfeeding, or planning to become pregnant before completing the study
  • Engaging in vigorous exercise more than 7 hours per week
  • Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years
  • Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
  • Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
  • Allergic to broccoli, moringa, mustard, or maitake mushrooms
  • Weighs less than 110 pounds
  • Diagnosis of sickle cell disease

Treatment and study plan

Avmacol Extra Strength with coating - 1 tablet

Dietary Supplement

Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Avmacol chewable wafer - 2 tablets

Dietary Supplement

Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)

Avmacol Extra Strength with coating - 2 tablets

Dietary Supplement

Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Primary outcomes

  1. Urine sulforaphane

    Time frame: 0, 2, 4, 8, and 24 hours

    Change from baseline levels of sulforaphane in urine

  2. Urine sulforaphane metabolites

    Time frame: 0, 2, 4, 8, and 24 hours

    Change from baseline levels of sulforaphane in urine

  3. Plasma glucoraphanin

    Time frame: 0, 1, 2, 4, 8, and 24 hours

    Change from baseline levels of plasma glucoraphanin

  4. Plasma sulforaphane

    Time frame: 0, 1, 2, 4, 8, and 24 hours

    Change from baseline levels of plasma sulforaphane

  5. Plasma sulforaphane metabolites

    Time frame: 0, 1, 2, 4, 8, and 24 hours

    Change from baseline levels of plasma sulforaphane metabolites

Study contacts

Contact information is provided by the study sponsor or research team.

Emily Ho, PhD

CONTACT

[email protected]

541-737-9559

Sandra Uesugi, RN, BSN, MS

CONTACT

[email protected]

541-737-3594

Sponsors and collaborators

Lead sponsor

Oregon State University

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 4, 2026
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.